Indivior Plc (LON:INDV) Rating Reaffirmed
Deutsche Bank now has a GBX 240.00 target on the 1.41B GBP market cap company or 23.71% upside potential. In a very recent research note revealed to investors on 10 December, Indivior Plc (LON:INDV) shares have had their Buy Rating kept steady by stock research analysts at Deutsche Bank.
From a total of 6 analysts covering Indivior Plc (LON:INDV) stock, 5 rate it a ”Buy”, 0 a “Sell”, and 1 a ”Hold”. This means that 83% of the ratings are positive. The highest target price is GBX 4.63 while the lowest target price is GBX 3.36. The mean of all analyst targets is GBX 3.95 with a 38.66% above today’s (GBX 194) stock price. Indivior Plc was the topic of 18 analyst reports since July 29, 2015 according to the firm StockzIntelligence Inc. Deutsche Bank maintained shares on November 30 with “Buy” rating. Citigroup upgraded shares to “Buy” rating and GBX 270 target share price in a report from a September 22. Jefferies maintained INDV stock in a recent report from November 25 with “Buy” rating. Finally, Morgan Stanley maintained the stock with “Equal-Weight” rating in a report issued on a July 24.
The stock increased 0.26% or GBX 0.5 on December 9, striking GBX 194. Approximately 1.89M shares of stock traded hands or 47.66% up from the average. Indivior PLC (LON:INDV) has declined 15.02% since May 13, 2015 and is downtrending. It has underperformed by 14.23% the S&P500.
Indivior PLC is a specialty pharmaceutical company. The company has a market cap of 1.41 billion GBP. The Firm and its subsidiaries are engaged in the development, manufacture, and sale of buprenorphine prescription drugs for the treatment of opioid dependence. It has 7.8 P/E ratio. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine overdose and the co-morbidity of schizophrenia.